Last reviewed · How we verify
Pivmecillinam hydrochloride tablets
Pivmecillinam hydrochloride is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis.
Pivmecillinam hydrochloride is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis. Used for Urinary tract infections.
At a glance
| Generic name | Pivmecillinam hydrochloride tablets |
|---|---|
| Also known as | Selexid® |
| Sponsor | Benova (Tianjin) Innovative medicine Research Co., Ltd. |
| Drug class | Beta-lactam antibiotic |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
It works by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, resulting in the disruption of the cell wall synthesis and ultimately leading to bacterial cell death.
Approved indications
- Urinary tract infections
Common side effects
- Gastrointestinal disturbances
- Allergic reactions
Key clinical trials
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection (PHASE3)
- Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: